Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer

European Journal of Cancer Prevention

Volumn 14, Issue 6, 2005, Pages 503-511

  Lux, Michael Patrick ^a   Ackermann, Sven ^a   Bani, Mayada R ^a   Nestle Krämling, Caroline ^b   Goecke, Timm O ^b   Niederacher, Dieter ^b   Bodden Heidrich, R ^b   Bender, Hans Georg ^b   Beckmann, Matthias Wilhelm ^a   Fasching, Peter Andreas ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Age of uptake; BRCA; Early cancer detection; Familial breast cancer; Familial ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER RISK; CONSULTATION; EARLY CANCER; EARLY DIAGNOSIS; FAMILIAL CANCER; FEMALE; GENE; GENETIC ANALYSIS; HEALTH; HEALTH CARE FACILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGE FACTORS; BREAST NEOPLASMS; DECISION MAKING; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PEDIGREE; RISK FACTORS;

EID: 28044452167     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200512000-00003     Document Type: Article

References (35)

1. American College of Obstetricians and Gynecologists (2003). ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 42, April 2003. Breast cancer screening. Obstet Gynecol 101: 821-831.
2. Beckmann MW, Niederacher D, Goecke TO, Bodden-Heidrich R, Schnürch HG, Bender HG (1997). Hochrisikofamilien mit Mamma- und Ovarialkarzinomen: Möglichkeiten der Beratung, genetischen Analyse und Früherkennung. Deutsches Ärzteblatt 94: A-161/B-135/C-131.
3. Beckmann MW, Werner Y, Renner SP, Fasching PA, Jap D, Kuschel B (2000). Krebsfrüherkennung in der frauenärztlichen Praxis. Der Gynäkologe 33: 474-482.
4. Beckmann MW, Fasching PA, Lux MP, Klemt D, Schroer B, Bodden-Heidrich R, et al. (2001). Das familiäre Mammakarzinom-Syndrom: prädiktive genetische Testung, Beratung und Betreuung. Med Welt 52: 385-390.
5. Beckmann MW, Fasching PA, Weiss JM, Magener A, Ortmann O (2003). Update primäres Mammakarzinom 2003 - GebFra-Refresher. Geburtsh Frauenheilk 63: R65-R85.
6. Breast Cancer Linkage Consortium (1999). Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91: 1310-1316.
7. Brekelmans CT (2003). Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15: 63-68.
8. Easton DF (2002). Familial risks of breast cancer. Breast Cancer Res 4: 179-181.
9. Easton DF on behalf of the BCLC (2003). Familial Breast Cancer Risks and the BCLC Database. The Breast Cancer Linkage Consortium (BCLC) and the International Collaborative Group on Familial Breast and Ovarian Cancer (ICG-FBOC). 14th General Meeting, Madrid.
10. Easton DF, Bishop DT, Ford D, Crockford GP and the Consortium BCL (1994). Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692.
11. Easton DF, Ford D, Bishop DT (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 256-271.
12. Eccles DM, Simmonds P, Goddard J, Coultas M, Lalloo F, Evans G, Haites N (1999). Management of hereditary breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers 15: 187-189.
13. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. (2002). Twenty-year follow-up of a randomized trial comapring total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233-1241.
14. Gordon PB (2002). Ultrasound for breast cancer screening and staging. Radiol Clin North Am 40: 431-441.
15. Jatoi I, Miller AB (2003). Why is breast cancer mortality declining? Lancet Oncol 4: 251-254.
16. Kiechle M (2000). Familiäres Mammakarzinom - eine Übersicht. Acta Chirurgica Austrica 32: 43-44.
17. Kiechle M, Schmutzler RK, Beckmann MW (2002). Prävention: Familiäres Mamma- und Ovarialkarzinom. Deutsches Ärzteblatt 99: A-1372.
18. Kinkel K, Vlastos G (2001). MR imaging: breast cancer staging and screening. Semin Surg Oncol 20: 187-196.
19. Krämer S, Ackermann S, Fasching PA, Kreis H, Pöhls U, Beckmann MW (2003). Steroidhormone und Ovarialkarzinom: Risiken und Nutzen. Geburtsh Frauenheilk 63: 615-623.
20. Krebsregister Saarland. www.krebsregister.saarland.de
21. Kuschel B, Aba F, Lux M, Jap D, Bender HG, Beckmann MW (2000). Mammakarzinom: Ermittlung des individuellen Erkrankungsrisikos und der Möglichkeiten zur Prävention. ZaeFQ 94: 231-237.
22. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, et al. (2000). Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215: 267-279.
23. Lagerlund M, Hedin A, Sparen P, Thurfjell E, Lambe M (2000). Attitudes, beliefs, and knowledge as predictors of nonattendance in a Swedish population-based mammography screening program. Prev Med 31: 417-428.
24. Lastao L, Joiner TE, Pettit JW, Chorot P, Sandin B (2001). Health belief and illness attitudes as predictors of breast cancer screening attendance. Eur J Public Health 11: 274-279.
25. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001). Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93: 1215-1223.
26. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, et al. (2000). Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88: 1393-1402.
27. Neise C, Rauchfuss M, Paepke S, Beier K, Lichtenegger W (2001). Risk perception and psychological strain in women with a family history of breast cancer. Onkologie 24: 470-475.
28. Paepke S, Schwarz-Boeger U, von Minckwitz G, Schultz-Zehden B, Kaufmann M, Beck H, Meden H, Kiechle M, Beckmann MW (2001). Brustkrebsfrüherkennung: Kenntnisstand und Akzeptanz in der weiblichen Bevölkerung. Deutsches Ärzteblatt 98: A-2178/B-1849/C-1741.
29. Ponder BAJ (2001). Cancer genetics. Nature 411: 336-341.
30. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 904-905.
31. Rosenstock IM (1975). Patient's compliance with health regimes. JAMA 234: 402-403.
32. Schmutzler RK, Kempe A, Kiechle M, Beckmann MW (1999). Klinische Beratung und Betreuung von Frauen mit erblicher Disposition für das Mamma- und Ovarialkarzinom. Dtsch Med Wschr 124: 563-566.
33. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M (2002). First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 63: 53-60.
34. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292: 1317-1325.
35. Wooster R, Weber BL (2003). Breast and ovarian cancer. N Engl J Med 348: 2339-2347.